Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Techniques & Tools

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2024 / Articles / Oct / Building Culture, Driving Growth
Manufacture Contract Manufacturing Services Business Practice Supply Chain Technology & Manufacturing Business & Trends Supply Chain

Building Culture, Driving Growth

Sitting Down With… Lars Petersen, President and CEO, FUJIFILM Diosynth Biotechnologies

10/02/2024 5 min read

Share

What inspires you to get up every day?
 

Patients, and the potential impact you can have on their lives. I spent eight years working for Genentech. When you make medicines for cancer, you often receive letters from patients and their families thanking you because you saved the life of their friend, their wife, their child, etc. This is such rewarding and purposeful feedback.

Now that I work at FUJIFILM Diosynth Biotechnologies, the exciting and passionate thing that makes me get up every day is having such a big platform to make a difference for patients. We work with innovators, big pharma, and biotech companies across the world. We see their pipelines and the impact to patients, and we hear stories on a much broader scale, which is very rewarding.

The more influential I am in my career, the more I can impact the agenda and direction of the entire Life Science industry. I feel as if I have to do better, run faster, and improve every day to get more medicines to patients. I think we all feel like this when working in this industry.

Did you find the switch from biopharma to CDMO challenging?


I certainly had to give it some thought. Specifically, I considered how I could apply my mindset to the CDMO business.

I had never seen the CDMO business as a purposeful part of the industry before; it was more an organization that merely churned products out whilst trying to make as much money as possible! To some extent, you still see that in the parts of the industry, but I'm trying to drive a different agenda to make sure that everything we do at this company has the same purpose and the focus that innovators have. At FUJIFILM Diosynth Biotechnologies our aim is to be Partners for Life. What we mean by that is we are doing much more than just developing and manufacturing biopharmaceuticals; we partner with and work alongside our clients every step of the way to bring life-changing therapies to patients around the world.

What is overwhelming is seeing the impact and the opportunities we have with so many companies in what we do. Multiple opportunities mean multiple products and multiple launches, so the speed and pressure are immense – more so than what you would see in an innovator company with fewer products. The work is never done. There are always new products coming and it takes some getting used to.

What’s your academic background and how has it helped your career?


I'm an engineer trained at the Technical University of Denmark, which – at the time – was the only place you could really get a master's degree in engineering in Denmark. I went straight out of school directly into the life sciences. My background is in automation and engineering in a manufacturing facility for life sciences. That’s how I found my way into the industry, starting very early at Novo Nordisk. My training in engineering has helped me a lot to understand how pharma manufacturing works. My tenure with Novo Nordisk gave me a deep understanding of what the big pharma companies need from their CDMOs. As President and CEO for FUJIFILM Diosynth Biotechnologies I can merge these two.

How has the culture in Denmark helped play a role in your career?


Denmark is a small country, but there are a handful of life science companies, including Novo Nordisk, which were very big at the time I was studying (though not as big as they are today of course!). Life sciences is a popular career, particularly for those in the Copenhagen area where most of the universities are situated, and the popularity of life sciences and my passion for helping people destined me for this industry. Jutland is home to the more traditional, mechanical industries with companies such as Danfoss, Grundfos, Lego, and Bang & Olufsen.

What are the key attributes of a successful CEO?


CEOs have changed a lot. You need to be mindful of the shifts and transformations in the world, and you have to understand how people are shifting. You must understand how business is changing and how to navigate between those shifts, as well as what is important to stakeholders and investors.

For me, it's all about people and stakeholders – and making sure you understand where the industry is going must be foundational to the strategy. Our 3 strategic pillars at FUJIFILM Diosynth Biotechnologies are; people first, transform the industry, and unprecedented delivery.

What are the challenges facing the CDMO sector?


The pharmaceutical industry has been in somewhat of a safe space for many years, with comfortably high profits. Compare this with other industries, such as the automotive or semiconductor industries, however, and it looks like pharma has been less transformative because it has been very lucrative, with few companies reducing their prices.

Now, there are many more biosimilars and generics, so there has been pressure – especially from governments – to make medicines cheaper and more accessible. There is immense pressure on innovators and supply chains are having to become more efficient. It's a good pressure to be under, however, because it makes us more efficient, lowers costs, and improves patient access to medicines.

More and more companies are building fewer facilities because of the improved efficiency that CDMOs bring to the supply chain. The more CDMOs, the bigger the network of facilities, and the more options an innovator has. A CDMO’s core business is to develop and manufacture medicines; an innovator’s role is to innovate and develop new medications and therapies to treat diseases and ultimately improve the lives of patients. It’s a perfect partnership, but you have to make sure you deliver and create with the right values. Making sure innovators can trust a CDMO is key.

What are you doing when you're not being a CEO?


I have a wife and three kids, as well as a dog and a house, so I'm extremely busy making sure I have enough time for all that! I like to travel. I enjoy history, and what we can learn from it. The more you dig back into history, the more you learn to look at the future. I also like music and going to concerts too. Every single day is wonderful. I would love to have 24 hours more every day, but I think I'm in a wonderful position being in a job with so many good people around me. The people behind what we do are the most important thing. If we can find the real purpose of who we are, we create a psychologically safe space to be in and get on with doing what we think is best for the world.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

Building a Resilient CGT Workforce
Advanced Medicine Contract Manufacturing Services Business Practice
Building a Resilient CGT Workforce

March 26, 2025

3 min read

With competition for skilled employees in cell and gene therapy manufacturing high, companies need to ensure they are investing in training and mentorship.

The Secret to Being a Good Employer
Contract Manufacturing Services Business Practice Profession
The Secret to Being a Good Employer

February 13, 2025

4 min read

Why you shouldn’t neglect the importance of blending people, culture, and strategy to foster success in a business.

AI Approach to Transdermal GLP-1s
Advanced Medicine Bioprocessing - Single Use Systems Bioprocessing - Upstream & Downstream Dosage Forms Contract Manufacturing Services Biosimilars Packaging Process Control Supply Chain Quality & Compliance
AI Approach to Transdermal GLP-1s

February 25, 2025

3 min read

How do you design, refine, and optimize novel GLP-1 drugs that could improve patient experiences? With a computer, of course.

Trends and Technologies in Oral Solid Dosage Formulation
Contract Manufacturing Services Small Molecules
Trends and Technologies in Oral Solid Dosage Formulation

January 16, 2025

3 min read

The trends and challenges in oral solid dosage formulations contribute to greater stability for drugs used by patients worldwide.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.